Right-Sizing Your Quality System to Maximize Exit Value
Where Quality Strategy Meets Exit StrategyLunch N’ Learn Details:
- Date: Wednesday, May 27, 2026
- Time: 12:00 PM – 1:00 PM PST
- Location: 9880 Campus Point Dr, San Diego, CA 92121 | Alexandria GradLabs – Terra Nova Conference Room
- Come ready to eat, learn, and connect – lunch to be provided
Register Now
Right-Sizing Your Quality System to Maximize Exit Value explores how quality systems are evaluated not just by regulators—but by investors, partners, and M&A diligence teams.
The session covers how buyers assess quality maturity, why reactive investments fail to create value, and how to build scalable, stage-appropriate systems that stand up to inspection and diligence scrutiny.
The focus is practical decision-making: what is required before first-in-human, Phase 3, and commercialization—and why timing matters.
Key Takeaways:
- The difference between inspection-ready and over-engineered systems
- Phase-gated quality requirements across milestones
- How quality systems can directly influence exit value
- What acquirers penalize vs. reward
Presenters
EVP, Product Development
Syner-G
Ray brings over 20 years of experience at the intersection of pharmaceutical science and business leadership, with a career defined by building high-performing teams and translating complex scientific programs into commercial results. At Syner-G, he leads a team of 60+ professionals spanning CMC development, regulatory CMC, quality, supply chain and project management delivering end-to-end solutions for biotech and pharmaceutical clients across biologics, small molecules, and peptides.
Ray has built a reputation for getting programs done right helping emerging biotechs, CDMOs, and established pharmaceutical companies navigate the full development continuum from early-stage IND through late-phase and commercialization. Clients turn to Ray and his team when the science is complex, the timelines are tight, and the stakes are high. His ability to combine deep technical expertise with sharp operational execution means programs move forward with fewer surprises and greater confidence. Whether standing up a CDMO partnership, resolving a development bottleneck, or building out a client’s internal capabilities, Ray brings the scientific credibility and strategic clarity that teams need to make critical decisions and deliver results.
Ray holds a Ph.D. in Organic Chemistry from the University of Illinois at Chicago and an MBA from Babson College.
Sr. Director, Quality and Compliance
Syner-G
Kelley Gillespie brings more than 30 years of Quality Assurance and Quality Control experience across pharmaceuticals, biologics, and medical devices. She specializes in quality system creation and management, supplier qualification, and compliance remediation, helping organizations strengthen their quality frameworks and meet regulatory expectations.
As Senior Director of Quality and Compliance at Syner-G, Kelley leads a team of consultants who serve as Heads of Quality for client organizations, overseeing QMS design, audits, and electronic quality system implementation. She previously held key quality roles at Acadia Pharmaceuticals, AstraZeneca, and Amgen, and is a Certified Quality Auditor through the American Society for Quality.
Next-Day Syner-G Office Hours:
Attendees are invited to schedule complimentary office hours the following day to discuss their quality strategy, upcoming milestones, or simply to connect.